Mobile

A study investigating the safety of radium-223 dichloride with abiraterone acetate and prednisone/prednisolone given to patients with castration-resistant prostate cancer that has spread to bone, and ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-003438-33

A study investigating the safety of radium-223 dichloride with abiraterone acetate and prednisone/prednisolone given to patients with castration-resistant prostate cancer that has spread to bone, and who never had chemotherapy before

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to compare the clinical benefit of radium-223 dichloride versus placebo in combination with abiraterone and prednisone/prednisolone in asymptomatic or mildly symptomatic chemotherapynaïve bone predominant metastatic castration-resistant prostate cancer patients.

Critère d'inclusion

  • Asymptomatic or mildly symptomatic chemotherapy-naïve bone predominant metastatic castration-resistant prostate cancer

Liens